Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14640430 | 0.76 | KAT2B (0.41) | KAT2B | |
| SCHEMBL136322 | 0.72 | KCNH2 (0.45) | FFAR1 | |
| SCHEMBL80967 | 0.70 | KAT2B (0.58) | KAT2B | |
| SCHEMBL14640401 | 0.69 | FFAR1 (0.49) | KAT2BFFAR1 | |
| SCHEMBL14640403 | 0.69 | IDH1 (0.45) | KAT2B | |
| SCHEMBL14640594 | 0.69 | FFAR1 (0.49) | KAT2BFFAR1 | |
| SCHEMBL5593844 | 0.69 | KAT2B (0.44) | KAT2B | |
| SCHEMBL5593840 | 0.69 | KAT2B (0.49) | KAT2B | |
| Hydrochloric Acid SCHEMBL9517520 | 0.69 | KAT2B (0.56) | KAT2B | |
| SCHEMBL5593775 | 0.69 | KAT2B (0.49) | KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001932-A2 | SUBSTITUTED ISOTHIAZOLONES AS INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007001932-A2 | SUBSTITUTED ISOTHIAZOLONES AS INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293374-A1 | Substituted isothiazolones | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293374-A1 | Substituted isothiazolones | LTB4R2, PTGES2, CYSLTR2 | KAT2B 1199/4885FFAR1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.